Anti-NLRC3 antibody
Specifications
| Product Cat#: | AB-06-3148 | |
| Product type: | Primary antibody | |
| Antigen: | NLRC3 | |
| Immunogen: | Peptide | |
| Species immunized: | Rabbit | |
| Isotype: | IgG | |
| Applications: | Immunocytochemistry (1:100-1:200); Immunohistochemistry (1:100-1:200); Flow Cytometry (1:50-1:00) | |
| Reactivity: | Mouse and Human | |
| Clonality (clone number): | Polyclonal | |
| Form: | Liquid | |
| Buffer: | 1*TBS (pH7.4), 0.5% BSA, 50% Glycerol. Preservative: 0.05% Sodium Azide. | |
| Concentration: | 1 mg/ml | |
| Purity: | Antigen affinity purified | |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. | |
| Alternative names: | CARD15-like antibody | |
| CARD15-like protein antibody | ||
| Caterpiller 16.2 antibody | ||
| Caterpiller protein 16.2 antibody | ||
| CLR16.2 antibody | ||
| FLJ00348 antibody | ||
| NLR family CARD domain containing 3 antibody | ||
| Nlrc3 antibody | ||
| NLRC3_HUMAN antibody | ||
| NOD-like receptor C3 antibody | ||
| NOD3 antibody | ||
| NOD3 protein antibody | ||
| Nucleotide-binding oligomerization domain protein 3 antibody | ||
| Nucleotide-binding oligomerization domain protein 3 caterpiller 16.2 antibody | ||
| nucleotide-binding oligomerization domain, leucine rich repeat and CARD |
Target information
Negative regulator of the innate immune response. Attenuates signaling pathways activated by Toll-like receptors (TLRs) and the DNA sensor STING/TMEM173 in response to pathogen-associated molecular patterns, such as intracellular poly(dA:dT), but not poly(I:C), or in response to DNA virus infection, including that of Herpes simplex virus 1 (HSV1) (PubMed:22863753, PubMed:24560620). May affect TLR4 signaling by acting at the level of TRAF6 ubiquitination, decreasing the activating ‘Lys-63’-linked ubiquitination and leaving unchanged the degradative ‘Lys-48’-linked ubiquitination (PubMed:22863753). Inhibits the PI3K-AKT-mTOR pathway possibly by directly interacting with the posphatidylinositol 3-kinase regulatory subunit p85 (PIK3R1/PIK3R2) and disrupting the association between PIK3R1/PIK3R2 and the catalytic subunit p110 (PIK3CA/PIK3CB/PIK3CD) and reducing PIK3R1/PIK3R2 activation. Via its regulation of the PI3K-AKT-mTOR pathway, controls cell proliferation, predominantly in intestinal epithelial cells (PubMed:27951586). May also affect NOD1- or NOD2-mediated NF-kappa-B activation (By similarity). Might also affect the inflammatory response by preventing NLRP3 inflammasome formation, CASP1 cleavage and IL1B maturation (By similarity).
Provider
Erpantech Laboratory
